Exploring DMTs: Blood-Brain Barrier Penetration and Cognitive Health Benefits

Author(s):

Gabriel Pardo, MD, FAAN,Martin Belkin, DO

Key Takeaways

Fingolimod, siponimod, and natalizumab can penetrate the blood-brain barrier, potentially impacting brain health directly.
The impact of DMTs on cognitive health is under investigation, with some evidence suggesting benefits in slowing cognitive decline.
Further research is needed to fully understand the mechanisms and extent of cognitive benefits provided by DMTs.

Panelists discuss how disease-modifying therapies (DMTs) like dimethyl fumarate, fingolimod, and cladribine demonstrate potential blood-brain barrier penetration, offering neuroprotective mechanisms. While these therapies show promise in mitigating cognitive decline, their impacts vary, highlighting the complex interplay among neuroinflammation, immune modulation, and cognitive preservation in multiple sclerosis management.

EP: 1.The Impact of Biomarkers and Modern Disease-Modifying Therapies in MS

EP: 2.Understanding PIRA in MS: Key Insights and Advances From ECTRIMS 2024

EP: 3.Biomarkers and Therapeutic Impact on PIRA

EP: 4.Disability Accumulation and Early Therapy: Insights from MAGNIFY-MS and High-Efficacy DMT Data

EP: 5.Addressing PIRA in Clinical Practice and Patient Conversations

Now Viewing

EP: 6.Exploring DMTs: Blood-Brain Barrier Penetration and Cognitive Health Benefits

Video content above is prompted by the following:

Which of the DMTs can penetrate the blood-brain barrier and have the potential to impact brain health directly?
What is our understanding of the impact of various DMTs on cognitive health?